Bile Acid Sequestrant global drug patents, pharmaceutical manufacturers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	WELCHOL	colesevelam hydrochloride	TABLET;ORAL	021176-001	May 26, 2000	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Aiping Pharm Inc	PREVALITE	cholestyramine	POWDER;ORAL	073263-001	Feb 22, 1996	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Aiping Pharm Inc	PREVALITE	cholestyramine	POWDER;ORAL	073263-002	Oct 30, 1997	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Chartwell Rx	LOCHOLEST LIGHT	cholestyramine	POWDER;ORAL	074562-001	Aug 15, 1996	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Chartwell Rx	LOCHOLEST LIGHT	cholestyramine	POWDER;ORAL	074562-002	Aug 15, 1996	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Chartwell Rx	LOCHOLEST	cholestyramine	POWDER;ORAL	074561-001	Aug 15, 1996	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Chartwell Rx	LOCHOLEST	cholestyramine	POWDER;ORAL	074561-002	Aug 15, 1996	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 9, 2026

Bile Acid Sequestrant Market Dynamics and Patent Landscape (2026): What Patents Protect Colesevelam, Colestipol, and Cholestyramine?

Bile acid sequestrants (BAS) are a mature lipid-lowering class with limited patent-driven innovation risk in the US. Patent protection is largely concentrated in formulation and manufacturing-method claims rather than new chemical entities. Commercial dynamics are shaped by generics for core actives (cholestyramine and colestipol), persistent brand strength for colesevelam-based products, and payer-driven substitution between BAS products and newer LDL-lowering agents.

Core conclusions (US focus, with global implications):

Active-ingredient patent estates for the class are largely expired or close to expiration in major markets, shifting enforcement to formulation, use, and manufacturing patents.
Colesevelam (bile acid sequestrant polymer) retains the most relevant brand-linked IP in practice through secondary patents around composition, dosage forms, and use.
Cholestyramine and colestipol are heavily generic, with litigation and licensing historically centered on brand-to-generic transitions and product line improvements.
Competitive pressure increasingly comes from high-efficacy LDL therapies (statins, ezetimibe, PCSK9 inhibitors, inclisiran, and oral ATP-citrate lyase inhibitors), pushing BAS into subsets of patients and combination regimens.
Regulatory exclusivity (new chemical entity exclusivity) is not a major driver for BAS today; the market is mostly governed by patent scope, Orange Book listings where applicable, and generic product equivalence.

What are the current market dynamics for bile acid sequestrants (BAS) in lipid management?

How is BAS positioned versus statins, ezetimibe, and PCSK9 pathway therapies?

BAS deliver LDL reductions via interruption of enterohepatic bile acid recycling, increasing hepatic bile acid synthesis and upregulating LDL receptors. In modern care pathways:

Statins remain first-line due to potency and long clinical history.
Ezetimibe is a common add-on with predictable efficacy and tolerability.
PCSK9 inhibitors and inclisiran capture high-risk patients needing greater LDL lowering, with adherence advantages.
BAS are used when clinicians seek bile acid-binding mechanism, when cost is central, or when patients cannot tolerate other classes.

Market behavior drivers:

Tolerability and adherence: constipation, bloating, and dosing burden affect persistence.
Drug-drug interactions: BAS can reduce absorption of concomitant drugs; timing separation and clinical monitoring matter.
Formulation evolution: tablets/packaging formats that improve usability can maintain share even with generic competition.
Payer preferences: formulary placement and step edits often push toward lower-cost generics unless brand-specific advantages exist.

What is the revenue exposure map across BAS products?

In practice, the main commercial revenue exposure centers on:

Colesevelam branded products (historically associated with stronger brand retention in the class).
Generic cholestyramine and colestipol volumes, where revenue is fragmented across multiple manufacturers.
Combination products that may not be strictly “BAS-only” growth drivers but influence overall BAS utilization.

Because BAS are mature and generics dominate, revenue exposure risk is more about share shifts and product switching than about single-expiring blockbuster patents.

What patents protect cholestyramine in the bile acid sequestrant class?

Which patent types remain relevant for cholestyramine after generic entry?

For cholestyramine, the live risk is usually not the active ingredient itself. Remaining IP is typically:

Composition of matter for specific formulations (less common for core powders).
Method-of-manufacture and particle size/process claims for improved stability or performance.
Packaging and dosing unit claims tied to product-specific formats, where granted.

How many patent families cover cholestyramine dosage forms in major markets?

The number of active, enforceable patent families is usually low relative to early lifecycle because:

The chemistry is old.
Many claims are either expired or never licensed to block standard generic formulations.

In the US, the practical enforcement focus historically shifts to any Orange Book-listed patents tied to specific listed products (when the brand has maintained such listings through formulation improvements). For cholestyramine, generic dominance usually narrows the set of meaningful enforceable rights.

What patents protect colestipol in the bile acid sequestrant class?

Do colestipol patent estates include new formulations or only legacy claims?

As with cholestyramine, colestipol’s core active is old. The enforceable landscape is commonly shaped by:

Secondary formulation claims (e.g., granulation characteristics, stability).
Process improvements used by certain manufacturers.
Orange Book-listed patents when a brand product keeps listings alive.

How does generic substitution affect colestipol’s patent relevance?

Generic substitution compresses value of any patent that does not clearly:

Block the ANDA product’s commercial viability, or
Require redesign that a generic cannot cost-effectively implement.

In BAS, substitution tends to be fast unless the brand’s formulation patents are both narrow and enforceable against the exact claimed features.

What patents protect colesevelam bile acid sequestrants and their formulations?

What is the key patent estate dynamic for colesevelam-based products?

Colesevelam’s brand positioning has historically been stronger than cholestyramine or colestipol due to patient-perceived tolerability and usability improvements for certain dosage presentations. That translates into a patent landscape more likely to have:

Formulation patents tied to a specific dosage form, manufacturing method, or physical properties.
Use or treatment patents, though method-of-use patents can be harder to enforce against generic products unless the generics induce the claimed use.

How many colesevelam formulation patent families typically matter for generic blocking?

In BAS generally, generic blocking requires that the generic’s product:

Practices the patented formulation or process, or
Triggers product-by-process infringement, or
Violates narrow combination or device/timing claims.

As a result, even when many patent documents exist in the universe, the enforceable subset is smaller and concentrated around product-specific features.

When does exclusivity end for bile acid sequestrants, and what timelines determine generic entry?

What exclusivity matters for older BAS actives?

For BAS actives introduced decades ago, today’s exclusivity analysis is dominated by:

Patent expiration (composition, formulation, and process claims).
ANDA approval status and Orange Book listings, including potential paragraph IV events.
Other regulatory exclusivity is typically not the key factor for this class.

How to read BAS generic-entry timing using Orange Book concepts

Generic entry timing in BAS typically follows this chain:

Identify Orange Book patents listed for each NDA/ANDA (where applicable) and their expiration dates.
Map any granted method/formulation claims to the generic product’s formulation details.
Track any ANDA litigation or settlement agreements that delay entry.

Because BAS are mature, much of the entry timing is already realized for core products. Current timing risk tends to be tied to late-life formulation patents rather than early chemical entity exclusivity.

What Paragraph IV challenges exist for bile acid sequestrants, and what do they signal?

What does a Paragraph IV in BAS usually target?

Paragraph IV for BAS products generally targets:

Formulation patents covering the exact physical/chemical characteristics needed for bioequivalence or performance.
Process patents that can be implicated through product-by-process arguments.
Use patents if the patented regimen is distinguishable and enforcement is feasible.

How does litigation change the commercial forecast for generic entry?

If patent litigation includes an injunction risk or a settlement with a delayed launch date, it can:

Hold back the next generic cohort.
Force payers to rely on incumbent pricing longer.
Create “wait-and-see” inventory strategies for wholesalers and pharmacies.

Because BAS market share is price-sensitive, even short delays can be economically meaningful.

What patent litigation affects bile acid sequestrant products most?

What is the typical litigation pattern for BAS?

BAS litigation generally follows an established pattern:

Brand (or brand-associated holder) sues on Orange Book-listed patents.
Generic counters with non-infringement and invalidity.
Courts address narrow claim scope, prosecution history, and factual comparability of formulations.

For a class like BAS, litigation often turns on whether the generic:

Uses a formulation/process within the claim parameters, and
Can be designed around without losing product functionality.

How strong is the patent estate for bile acid sequestrant formulations?

Strength metrics that matter for licensing and enforcement

For BAS, practical “strength” is usually measured by:

Number of US Orange Book-listed patents per product at decision time.
Remaining term length at the generic filing window.
Claim breadth versus generic design-around feasibility.
Evidence of claim coverage of common generic formulation approaches.

What is the risk profile by product?

Cholestyramine: typically high generic availability; patent leverage usually limited to narrow product-specific formulation/process improvements.
Colestipol: similar pattern, with enforcement usually constrained by narrow claim scope.
Colesevelam: greater likelihood of enforceable formulation/process patents, supporting longer commercial defensibility relative to the rest of the class.

What generic entry risks exist for bile acid sequestrants in 2026?

Where can new competition still emerge if actives are generic?

New entry risk is mostly “late-life”:

New dosage forms (tablet vs powder vs chewable or packed formats).
Improved manufacturing approaches that may still infringe older formulation/process claims.
Litigation-driven product launches after an appeal decision or settlement trigger.

How does biosimilar risk apply to BAS?

BAS are small molecules, so biosimilar risk is not applicable. The class is subject to the generic pathway (ANDA) rather than biosimilar pathways (BLA).

How do bile acid sequestrant patents compare across cholestyramine, colestipol, and colesevelam?

Comparison matrix: IP relevance and commercialization

Drug (BAS)	Dominant market structure	Typical patent leverage	Practical generic risk driver
Cholestyramine	Predominantly generic	Narrow formulation/process where listed	Design-around cost vs performance constraints
Colestipol	Mostly generic	Usually limited to specific process/formulation improvements	Unexpired secondary claims mapped to generic process
Colesevelam	Stronger brand retention historically	More formulation/secondary patents tied to product use	Late-expiring formulation/process patents; litigation settlements

What is the Orange Book status of bile acid sequestrant products?

Why Orange Book status is central for BAS

In BAS, the Orange Book is the fastest way to identify whether there are:

Still-active listed patents for a specific branded product/NDA, and
Whether recent ANDA filings triggered litigation or settlement.

For this class, Orange Book status is typically:

Thin for core actives that have long since expired.
Thicker where brand holders maintain formulation improvements under separate listings.

Which companies hold commercial BAS share, and how does patent position affect them?

Competitive landscape mechanics

BAS pricing and share are driven by:

Net price and wholesaler contracting,
Formulary status and step therapy,
Switching resistance due to tolerability and patient stability.

Companies that can maintain brand or secure long-lived formulations with defensible IP can:

Limit immediate generic erosion,
Sustain higher gross-to-net ratios,
Use litigation leverage as a time buffer for marketing and contracting.

Which manufacturing and IP barriers protect bile acid sequestrant supply?

What barriers matter most in BAS?

In BAS, manufacturing barriers are less about chemical synthesis and more about:

Particle size and binding characteristics affecting dissolution/performance.
Stability of formulation under shelf-life conditions.
Process controls that may be protected by manufacturing patents.

These factors can:

Raise cost for generic manufacturers if a narrow process is required,
Create infringement arguments under product-by-process frameworks.

What regulatory pathway issues shape BAS market entry and labeling?

How do labeling and substitution rules affect generic uptake?

Even with regulatory approval, uptake depends on:

Interchangeability and substitution by pharmacists,
Formulary listing and payer policy,
Clinical guideline alignment.

Because BAS actives are interchangeable in mechanism, regulators rarely create barriers at the class level. The barrier is usually patent scope for listed formulation/process patents tied to specific products.

Key Takeaways

BAS are mature and mostly generic; IP leverage is concentrated in secondary formulation and manufacturing-method patents, not new chemical entity protection.
Colesevelam generally shows the most meaningful brand-linked patent relevance in the class; cholestyramine and colestipol are more constrained by generic availability.
Generic entry timing is governed by patent expiration and Orange Book-listed patents plus any litigation or settlement delays, not by broad exclusivity.
In the current lipid management landscape, BAS growth is driven more by payer dynamics and tolerability positioning than by patent-driven innovation.
Biosimilar risk does not apply; the class is relevant to ANDA-based generic competition.

FAQs

How do formulation patents for colesevelam-based bile acid sequestrants typically get enforced against generic ANDA products?
What settlement agreement terms most commonly delay generic bile acid sequestrant launches?
Which Orange Book-listed patents for BAS products are most likely to be attacked via Paragraph IV?
Do method-of-use patents for lipid-lowering with bile acid sequestrants meaningfully block generics?
How do BAS drug-drug interaction labeling requirements affect pharmacy substitution and real-world uptake of generics?

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA website).
U.S. Food and Drug Administration. ANDA approval pathway guidance and regulatory framework for generic drugs. (FDA website).
U.S. Court of Appeals for the Federal Circuit. Hatch-Waxman patent litigation and Paragraph IV framework decisions (various). (Federal Circuit website).